Cellular Biomedicine held an official opening for its new Shanghai CAR-T manufacturing facility, located in Zhangjiang High-Tech Park. The company now has three China plants (Beijing, Shanghai, Wuxi), which will provide clinical trial supplies of its CAR-T candidate. In 2015, Cellular Biomedicine formed a partnership with the Chinese PLA General Hospital (the 301 hospital) of Beijing for the CAR-T immunotherapy. CBMG says it now has the ability to produce all plasmids and viral vectors for the therapy in-house.
Source: China Biotoday
